ID   TYDP1_HUMAN             Reviewed;         608 AA.
AC   Q9NUW8; Q2HXX4; Q86TV8; Q96BK7; Q9NZM7; Q9NZM8;
DT   24-OCT-2003, integrated into UniProtKB/Swiss-Prot.
DT   24-OCT-2003, sequence version 2.
DT   28-JUN-2023, entry version 179.
DE   RecName: Full=Tyrosyl-DNA phosphodiesterase 1;
DE            Short=Tyr-DNA phosphodiesterase 1;
DE            EC=3.1.4.- {ECO:0000269|PubMed:15111055, ECO:0000269|PubMed:16141202, ECO:0000269|PubMed:22822062};
GN   Name=TDP1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Placenta;
RA   Li W.B., Gruber C., Jessee J., Polayes D.;
RT   "Full-length cDNA libraries and normalization.";
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ASP-95; LEU-101; THR-134;
RP   GLY-187; GLN-304 AND ALA-569.
RG   NIEHS SNPs program;
RL   Submitted (JAN-2006) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12508121; DOI=10.1038/nature01348;
RA   Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C.,
RA   Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A.,
RA   Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S., Sun H.,
RA   Du H., Pepin K., Artiguenave F., Robert C., Cruaud C., Bruels T.,
RA   Jaillon O., Friedlander L., Samson G., Brottier P., Cure S., Segurens B.,
RA   Aniere F., Samain S., Crespeau H., Abbasi N., Aiach N., Boscus D.,
RA   Dickhoff R., Dors M., Dubois I., Friedman C., Gouyvenoux M., James R.,
RA   Madan A., Mairey-Estrada B., Mangenot S., Martins N., Menard M., Oztas S.,
RA   Ratcliffe A., Shaffer T., Trask B., Vacherie B., Bellemere C., Belser C.,
RA   Besnard-Gonnet M., Bartol-Mavel D., Boutard M., Briez-Silla S.,
RA   Combette S., Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C.,
RA   Muselet D., Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P.,
RA   Trybou A., Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M.,
RA   Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V.,
RA   Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L., Verdier J.,
RA   Verdier-Discala C., Hillier L.W., Fulton L., McPherson J., Matsuda F.,
RA   Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W., Quetier F.,
RA   Waterston R., Hood L., Weissenbach J.;
RT   "The DNA sequence and analysis of human chromosome 14.";
RL   Nature 421:601-607(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 6-608 (ISOFORM 1).
RX   PubMed=10521354; DOI=10.1126/science.286.5439.552;
RA   Pouliot J.J., Yao K.C., Robertson C.A., Nash H.A.;
RT   "Yeast gene for a Tyr-DNA phosphodiesterase that repairs topoisomerase I
RT   complexes.";
RL   Science 286:552-555(1999).
RN   [7]
RP   SIMILARITY TO PHOSPHOLIPASE D SUPERFAMILY, AND MUTAGENESIS OF HIS-263;
RP   LYS-265; HIS-493 AND LYS-495.
RX   PubMed=11572945; DOI=10.1073/pnas.211429198;
RA   Interthal H., Pouliot J.J., Champoux J.J.;
RT   "The tyrosyl-DNA phosphodiesterase Tdp1 is a member of the phospholipase D
RT   superfamily.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:12009-12014(2001).
RN   [8]
RP   FUNCTION.
RX   PubMed=12023295; DOI=10.1074/jbc.m204688200;
RA   Inamdar K.V., Pouliot J.J., Zhou T., Lees-Miller S.P., Rasouli-Nia A.,
RA   Povirk L.F.;
RT   "Conversion of phosphoglycolate to phosphate termini on 3' overhangs of DNA
RT   double strand breaks by the human tyrosyl-DNA phosphodiesterase hTdp1.";
RL   J. Biol. Chem. 277:27162-27168(2002).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVE SITE, ENZYME MECHANISM, AND
RP   MUTAGENESIS OF HIS-263; LYS-265; ASN-283; GLN-294; HIS-493; LYS-495;
RP   ASN-516 AND GLU-538.
RX   PubMed=15111055; DOI=10.1016/j.jmb.2004.03.013;
RA   Raymond A.C., Rideout M.C., Staker B., Hjerrild K., Burgin A.B. Jr.;
RT   "Analysis of human tyrosyl-DNA phosphodiesterase I catalytic residues.";
RL   J. Mol. Biol. 338:895-906(2004).
RN   [10]
RP   FUNCTION.
RX   PubMed=15811850; DOI=10.1074/jbc.m502148200;
RA   Raymond A.C., Staker B.L., Burgin A.B. Jr.;
RT   "Substrate specificity of tyrosyl-DNA phosphodiesterase I (Tdp1).";
RL   J. Biol. Chem. 280:22029-22035(2005).
RN   [11]
RP   FUNCTION, CATALYTIC ACTIVITY, AND CHARACTERIZATION OF VARIANT SCAN1
RP   ARG-493.
RX   PubMed=16141202; DOI=10.1074/jbc.m508898200;
RA   Interthal H., Chen H.J., Champoux J.J.;
RT   "Human Tdp1 cleaves a broad spectrum of substrates, including phosphoamide
RT   linkages.";
RL   J. Biol. Chem. 280:36518-36528(2005).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-61, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-147 AND SER-148, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=22822062; DOI=10.1074/jbc.m112.393983;
RA   Gao R., Huang S.Y., Marchand C., Pommier Y.;
RT   "Biochemical characterization of human Tyrosyl DNA Phosphodiesterase 2
RT   (TDP2/TTRAP): a Mg2+/Mn2+-dependent phosphodiesterase specific for the
RT   repair of topoisomerase cleavage complexes.";
RL   J. Biol. Chem. 287:30842-30852(2012).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-61, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 149-608 IN COMPLEXES WITH
RP   SUBSTRATE; VANADATE AND TUNGSTATE, AND ACTIVE SITE.
RX   PubMed=12470949; DOI=10.1016/s0022-2836(02)01154-3;
RA   Davies D.R., Interthal H., Champoux J.J., Hol W.G.J.;
RT   "Insights into substrate binding and catalytic mechanism of human tyrosyl-
RT   DNA phosphodiesterase (Tdp1) from vanadate and tungstate-inhibited
RT   structures.";
RL   J. Mol. Biol. 324:917-932(2002).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (1.69 ANGSTROMS) OF 149-608, AND SUBUNIT.
RX   PubMed=11839309; DOI=10.1016/s0969-2126(02)00707-4;
RA   Davies D.R., Interthal H., Champoux J.J., Hol W.G.J.;
RT   "The crystal structure of human tyrosyl-DNA phosphodiesterase, Tdp1.";
RL   Structure 10:237-248(2002).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.03 ANGSTROMS) OF 149-608.
RX   PubMed=12618186; DOI=10.1016/s1074-5521(03)00021-8;
RA   Davies D.R., Interthal H., Champoux J.J., Hol W.G.J.;
RT   "Crystal structure of a transition state mimic for TDP1 assembled from
RT   vanadate, DNA, and a topoisomerase I-derived peptide.";
RL   Chem. Biol. 10:139-147(2003).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 149-608 IN COMPLEXES WITH
RP   SUBSTRATES.
RX   PubMed=14761185; DOI=10.1021/jm030487x;
RA   Davies D.R., Interthal H., Champoux J.J., Hol W.G.J.;
RT   "Explorations of peptide and oligonucleotide binding sites of tyrosyl-DNA
RT   phosphodiesterase using vanadate complexes.";
RL   J. Med. Chem. 47:829-837(2004).
RN   [22]
RP   VARIANT SCAN1 ARG-493, VARIANT LEU-566, AND TISSUE SPECIFICITY.
RX   PubMed=12244316; DOI=10.1038/ng987;
RA   Takashima H., Boerkoel C.F., John J., Saifi G.M., Salih M.A.M.,
RA   Armstrong D., Mao Y., Quiocho F.A., Roa B.B., Nakagawa M., Stockton D.W.,
RA   Lupski J.R.;
RT   "Mutation of TDP1, encoding a topoisomerase I-dependent DNA damage repair
RT   enzyme, in spinocerebellar ataxia with axonal neuropathy.";
RL   Nat. Genet. 32:267-272(2002).
RN   [23]
RP   CHARACTERIZATION OF VARIANT SCAN1 ARG-493, SUBCELLULAR LOCATION, AND
RP   PHOSPHORYLATION.
RX   PubMed=15647511; DOI=10.1093/nar/gki170;
RA   Zhou T., Lee J.W., Tatavarthi H., Lupski J.R., Valerie K., Povirk L.F.;
RT   "Deficiency in 3'-phosphoglycolate processing in human cells with a
RT   hereditary mutation in tyrosyl-DNA phosphodiesterase (TDP1).";
RL   Nucleic Acids Res. 33:289-297(2005).
RN   [24]
RP   CHARACTERIZATION OF VARIANT SCAN1 ARG-493.
RX   PubMed=15920477; DOI=10.1038/sj.emboj.7600694;
RA   Interthal H., Chen H.J., Kehl-Fie T.E., Zotzmann J., Leppard J.B.,
RA   Champoux J.J.;
RT   "SCAN1 mutant Tdp1 accumulates the enzyme-DNA intermediate and causes
RT   camptothecin hypersensitivity.";
RL   EMBO J. 24:2224-2233(2005).
RN   [25]
RP   CHARACTERIZATION OF VARIANT SCAN1 ARG-493, AND TISSUE SPECIFICITY.
RX   PubMed=17948061; DOI=10.1038/sj.emboj.7601885;
RA   Hirano R., Interthal H., Huang C., Nakamura T., Deguchi K., Choi K.,
RA   Bhattacharjee M.B., Arimura K., Umehara F., Izumo S., Northrop J.L.,
RA   Salih M.A.M., Inoue K., Armstrong D.L., Champoux J.J., Takashima H.,
RA   Boerkoel C.F.;
RT   "Spinocerebellar ataxia with axonal neuropathy: consequence of a Tdp1
RT   recessive neomorphic mutation?";
RL   EMBO J. 26:4732-4743(2007).
CC   -!- FUNCTION: DNA repair enzyme that can remove a variety of covalent
CC       adducts from DNA through hydrolysis of a 3'-phosphodiester bond, giving
CC       rise to DNA with a free 3' phosphate. Catalyzes the hydrolysis of dead-
CC       end complexes between DNA and the topoisomerase I active site tyrosine
CC       residue. Hydrolyzes 3'-phosphoglycolates on protruding 3' ends on DNA
CC       double-strand breaks due to DNA damage by radiation and free radicals.
CC       Acts on blunt-ended double-strand DNA breaks and on single-stranded
CC       DNA. Has low 3'exonuclease activity and can remove a single nucleoside
CC       from the 3'end of DNA and RNA molecules with 3'hydroxyl groups. Has no
CC       exonuclease activity towards DNA or RNA with a 3'phosphate.
CC       {ECO:0000269|PubMed:12023295, ECO:0000269|PubMed:15111055,
CC       ECO:0000269|PubMed:15811850, ECO:0000269|PubMed:16141202,
CC       ECO:0000269|PubMed:22822062}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.08 uM for 14-mer single-stranded oligo with a 3'-phosphotyrosine
CC         {ECO:0000269|PubMed:22822062};
CC         Note=kcat is 7 sec(-1) with single-stranded 5'-tyrosyl DNA as
CC         substrate.;
CC   -!- SUBUNIT: Monomer. {ECO:0000269|PubMed:11839309}.
CC   -!- INTERACTION:
CC       Q9NUW8; P46379-2: BAG6; NbExp=3; IntAct=EBI-2902553, EBI-10988864;
CC       Q9NUW8; Q9H816: DCLRE1B; NbExp=3; IntAct=EBI-2902553, EBI-3508943;
CC       Q9NUW8; Q9BYZ2: LDHAL6B; NbExp=3; IntAct=EBI-2902553, EBI-1108377;
CC       Q9NUW8; A4FUJ8: MKL1; NbExp=3; IntAct=EBI-2902553, EBI-21250407;
CC       Q9NUW8; O75925: PIAS1; NbExp=3; IntAct=EBI-2902553, EBI-629434;
CC       Q9NUW8; Q9NS23-4: RASSF1; NbExp=3; IntAct=EBI-2902553, EBI-438710;
CC       Q9NUW8; Q6ZNA4-2: RNF111; NbExp=3; IntAct=EBI-2902553, EBI-21535400;
CC       Q9NUW8; Q8N488: RYBP; NbExp=3; IntAct=EBI-2902553, EBI-752324;
CC       Q9NUW8; Q8IUW3: SPATA2L; NbExp=3; IntAct=EBI-2902553, EBI-2510414;
CC       Q9NUW8; Q15554-4: TERF2; NbExp=3; IntAct=EBI-2902553, EBI-25840535;
CC       Q9NUW8; Q08AM6: VAC14; NbExp=3; IntAct=EBI-2902553, EBI-2107455;
CC       Q9NUW8; P18887: XRCC1; NbExp=2; IntAct=EBI-2902553, EBI-947466;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:15647511}. Cytoplasm
CC       {ECO:0000269|PubMed:15647511}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9NUW8-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NUW8-2; Sequence=VSP_055765, VSP_055766;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed. Similar expression
CC       throughout the central nervous system (whole brain, amygdala, caudate
CC       nucleus, cerebellum, cerebral cortex, frontal lobe, hippocampus,
CC       medulla oblongata, occipital lobe, putamen, substantia nigra, temporal
CC       lobe, thalamus, nucleus accumbens and spinal cord) and increased
CC       expression in testis and thymus. {ECO:0000269|PubMed:12244316,
CC       ECO:0000269|PubMed:17948061}.
CC   -!- PTM: Phosphorylated on serine and/or threonine residues, but not on
CC       tyrosine residues. {ECO:0000269|PubMed:15647511}.
CC   -!- DISEASE: Spinocerebellar ataxia, autosomal recessive, with axonal
CC       neuropathy 1 (SCAN1) [MIM:607250]: A form of spinocerebellar ataxia, a
CC       clinically and genetically heterogeneous group of cerebellar disorders.
CC       Patients show progressive incoordination of gait and often poor
CC       coordination of hands, speech and eye movements, due to degeneration of
CC       the cerebellum with variable involvement of the brainstem and spinal
CC       cord. SCAN1 is an autosomal recessive cerebellar ataxia (ARCA)
CC       associated with peripheral axonal motor and sensory neuropathy, distal
CC       muscular atrophy, pes cavus and steppage gait as seen in Charcot-Marie-
CC       Tooth neuropathy. All affected individuals have normal intelligence.
CC       {ECO:0000269|PubMed:12244316, ECO:0000269|PubMed:15647511,
CC       ECO:0000269|PubMed:15920477, ECO:0000269|PubMed:16141202,
CC       ECO:0000269|PubMed:17948061}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the tyrosyl-DNA phosphodiesterase family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/tdp1/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; BX161451; CAD61915.1; -; mRNA.
DR   EMBL; AK001952; BAA91997.1; -; mRNA.
DR   EMBL; DQ367843; ABC79301.1; -; Genomic_DNA.
DR   EMBL; AL137128; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC015474; AAH15474.1; -; mRNA.
DR   EMBL; AF182002; AAF65623.1; -; mRNA.
DR   EMBL; AF182003; AAF65624.1; -; mRNA.
DR   CCDS; CCDS9888.1; -. [Q9NUW8-1]
DR   RefSeq; NP_001008744.1; NM_001008744.1. [Q9NUW8-1]
DR   RefSeq; NP_060789.2; NM_018319.3. [Q9NUW8-1]
DR   RefSeq; XP_005267904.1; XM_005267847.2.
DR   RefSeq; XP_005267905.1; XM_005267848.2. [Q9NUW8-1]
DR   RefSeq; XP_006720260.1; XM_006720197.3. [Q9NUW8-1]
DR   RefSeq; XP_006720261.1; XM_006720198.3.
DR   RefSeq; XP_011535244.1; XM_011536942.2. [Q9NUW8-1]
DR   RefSeq; XP_011535245.1; XM_011536943.2.
DR   RefSeq; XP_016876928.1; XM_017021439.1.
DR   RefSeq; XP_016876931.1; XM_017021442.1.
DR   RefSeq; XP_016876932.1; XM_017021443.1.
DR   RefSeq; XP_016876933.1; XM_017021444.1.
DR   PDB; 1JY1; X-ray; 1.69 A; A=149-608.
DR   PDB; 1MU7; X-ray; 2.00 A; A/B=149-608.
DR   PDB; 1MU9; X-ray; 2.05 A; A/B=149-608.
DR   PDB; 1NOP; X-ray; 2.30 A; A/B=149-608.
DR   PDB; 1QZQ; X-ray; 2.40 A; A/B=149-608.
DR   PDB; 1RFF; X-ray; 1.70 A; A/B=149-608.
DR   PDB; 1RFI; X-ray; 2.20 A; A/B=149-608.
DR   PDB; 1RG1; X-ray; 2.10 A; A/B=149-608.
DR   PDB; 1RG2; X-ray; 2.10 A; A/B=149-608.
DR   PDB; 1RGT; X-ray; 2.00 A; A/B=149-608.
DR   PDB; 1RGU; X-ray; 2.22 A; A/B=149-608.
DR   PDB; 1RH0; X-ray; 2.30 A; A/B=149-608.
DR   PDB; 5NW9; X-ray; 2.04 A; A/B=149-608.
DR   PDB; 5NWA; X-ray; 3.20 A; A/B=149-608.
DR   PDB; 6DHU; X-ray; 1.63 A; A/B=148-608.
DR   PDB; 6DIE; X-ray; 1.78 A; A/B=148-608.
DR   PDB; 6DIH; X-ray; 1.78 A; A/B=148-608.
DR   PDB; 6DIM; X-ray; 1.81 A; A/B=148-608.
DR   PDB; 6DJD; X-ray; 1.78 A; A/B=148-608.
DR   PDB; 6DJE; X-ray; 1.71 A; A/B=148-608.
DR   PDB; 6DJF; X-ray; 1.67 A; A/B=148-608.
DR   PDB; 6DJG; X-ray; 1.88 A; A/B=148-608.
DR   PDB; 6DJH; X-ray; 1.92 A; A/B=148-608.
DR   PDB; 6DJI; X-ray; 1.75 A; A/B=148-608.
DR   PDB; 6DJJ; X-ray; 1.74 A; A/B=148-608.
DR   PDB; 6MJ5; X-ray; 1.85 A; A/B=149-608.
DR   PDB; 6MYZ; X-ray; 1.66 A; A/B=148-608.
DR   PDB; 6MZ0; X-ray; 1.97 A; A/B=148-608.
DR   PDB; 6N0D; X-ray; 1.45 A; A/B=148-608.
DR   PDB; 6N0N; X-ray; 1.48 A; A/B=148-608.
DR   PDB; 6N0O; X-ray; 1.94 A; A/B=148-608.
DR   PDB; 6N0R; X-ray; 1.54 A; A/B=148-608.
DR   PDB; 6N17; X-ray; 1.64 A; A/B=148-608.
DR   PDB; 6N19; X-ray; 1.50 A; A/B=148-608.
DR   PDB; 6W4R; X-ray; 1.82 A; A/B=148-608.
DR   PDB; 6W7J; X-ray; 1.49 A; A/B=148-608.
DR   PDB; 6W7K; X-ray; 1.70 A; A/B=148-608.
DR   PDB; 6W7L; X-ray; 1.86 A; A/B=148-608.
DR   PDBsum; 1JY1; -.
DR   PDBsum; 1MU7; -.
DR   PDBsum; 1MU9; -.
DR   PDBsum; 1NOP; -.
DR   PDBsum; 1QZQ; -.
DR   PDBsum; 1RFF; -.
DR   PDBsum; 1RFI; -.
DR   PDBsum; 1RG1; -.
DR   PDBsum; 1RG2; -.
DR   PDBsum; 1RGT; -.
DR   PDBsum; 1RGU; -.
DR   PDBsum; 1RH0; -.
DR   PDBsum; 5NW9; -.
DR   PDBsum; 5NWA; -.
DR   PDBsum; 6DHU; -.
DR   PDBsum; 6DIE; -.
DR   PDBsum; 6DIH; -.
DR   PDBsum; 6DIM; -.
DR   PDBsum; 6DJD; -.
DR   PDBsum; 6DJE; -.
DR   PDBsum; 6DJF; -.
DR   PDBsum; 6DJG; -.
DR   PDBsum; 6DJH; -.
DR   PDBsum; 6DJI; -.
DR   PDBsum; 6DJJ; -.
DR   PDBsum; 6MJ5; -.
DR   PDBsum; 6MYZ; -.
DR   PDBsum; 6MZ0; -.
DR   PDBsum; 6N0D; -.
DR   PDBsum; 6N0N; -.
DR   PDBsum; 6N0O; -.
DR   PDBsum; 6N0R; -.
DR   PDBsum; 6N17; -.
DR   PDBsum; 6N19; -.
DR   PDBsum; 6W4R; -.
DR   PDBsum; 6W7J; -.
DR   PDBsum; 6W7K; -.
DR   PDBsum; 6W7L; -.
DR   AlphaFoldDB; Q9NUW8; -.
DR   SASBDB; Q9NUW8; -.
DR   SMR; Q9NUW8; -.
DR   BioGRID; 120890; 31.
DR   CORUM; Q9NUW8; -.
DR   IntAct; Q9NUW8; 27.
DR   MINT; Q9NUW8; -.
DR   STRING; 9606.ENSP00000337353; -.
DR   BindingDB; Q9NUW8; -.
DR   ChEMBL; CHEMBL1075138; -.
DR   GlyGen; Q9NUW8; 8 sites, 1 O-linked glycan (8 sites).
DR   iPTMnet; Q9NUW8; -.
DR   PhosphoSitePlus; Q9NUW8; -.
DR   BioMuta; TDP1; -.
DR   DMDM; 37999797; -.
DR   EPD; Q9NUW8; -.
DR   jPOST; Q9NUW8; -.
DR   MassIVE; Q9NUW8; -.
DR   MaxQB; Q9NUW8; -.
DR   PaxDb; Q9NUW8; -.
DR   PeptideAtlas; Q9NUW8; -.
DR   ProteomicsDB; 69739; -.
DR   ProteomicsDB; 82725; -. [Q9NUW8-1]
DR   Antibodypedia; 26468; 370 antibodies from 31 providers.
DR   DNASU; 55775; -.
DR   Ensembl; ENST00000335725.9; ENSP00000337353.4; ENSG00000042088.14. [Q9NUW8-1]
DR   Ensembl; ENST00000393454.6; ENSP00000377099.2; ENSG00000042088.14. [Q9NUW8-1]
DR   GeneID; 55775; -.
DR   KEGG; hsa:55775; -.
DR   MANE-Select; ENST00000335725.9; ENSP00000337353.4; NM_018319.4; NP_060789.2.
DR   UCSC; uc001xxy.4; human. [Q9NUW8-1]
DR   AGR; HGNC:18884; -.
DR   CTD; 55775; -.
DR   DisGeNET; 55775; -.
DR   GeneCards; TDP1; -.
DR   GeneReviews; TDP1; -.
DR   HGNC; HGNC:18884; TDP1.
DR   HPA; ENSG00000042088; Low tissue specificity.
DR   MalaCards; TDP1; -.
DR   MIM; 607198; gene.
DR   MIM; 607250; phenotype.
DR   neXtProt; NX_Q9NUW8; -.
DR   OpenTargets; ENSG00000042088; -.
DR   Orphanet; 94124; Spinocerebellar ataxia with axonal neuropathy type 1.
DR   PharmGKB; PA421; -.
DR   VEuPathDB; HostDB:ENSG00000042088; -.
DR   eggNOG; KOG2031; Eukaryota.
DR   GeneTree; ENSGT00390000002211; -.
DR   HOGENOM; CLU_010413_4_0_1; -.
DR   InParanoid; Q9NUW8; -.
DR   OMA; PLIKECW; -.
DR   OrthoDB; 930461at2759; -.
DR   PhylomeDB; Q9NUW8; -.
DR   TreeFam; TF105989; -.
DR   BRENDA; 3.1.4.1; 2681.
DR   PathwayCommons; Q9NUW8; -.
DR   Reactome; R-HSA-5693571; Nonhomologous End-Joining (NHEJ).
DR   SABIO-RK; Q9NUW8; -.
DR   SignaLink; Q9NUW8; -.
DR   SIGNOR; Q9NUW8; -.
DR   BioGRID-ORCS; 55775; 20 hits in 1161 CRISPR screens.
DR   ChiTaRS; TDP1; human.
DR   EvolutionaryTrace; Q9NUW8; -.
DR   GeneWiki; TDP1; -.
DR   GenomeRNAi; 55775; -.
DR   Pharos; Q9NUW8; Tchem.
DR   PRO; PR:Q9NUW8; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   RNAct; Q9NUW8; protein.
DR   Bgee; ENSG00000042088; Expressed in oocyte and 141 other tissues.
DR   ExpressionAtlas; Q9NUW8; baseline and differential.
DR   Genevisible; Q9NUW8; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0017005; F:3'-tyrosyl-DNA phosphodiesterase activity; IDA:UniProtKB.
DR   GO; GO:0003690; F:double-stranded DNA binding; IDA:UniProtKB.
DR   GO; GO:0004527; F:exonuclease activity; IEA:UniProtKB-KW.
DR   GO; GO:0003697; F:single-stranded DNA binding; IDA:UniProtKB.
DR   GO; GO:0006281; P:DNA repair; IDA:UniProtKB.
DR   GO; GO:0006302; P:double-strand break repair; IDA:UniProtKB.
DR   GO; GO:0000012; P:single strand break repair; IDA:UniProtKB.
DR   CDD; cd09193; PLDc_mTdp1_1; 1.
DR   CDD; cd09195; PLDc_mTdp1_2; 1.
DR   Gene3D; 3.30.870.10; Endonuclease Chain A; 2.
DR   InterPro; IPR010347; Tdp1.
DR   PANTHER; PTHR12415; TYROSYL-DNA PHOSPHODIESTERASE 1; 1.
DR   PANTHER; PTHR12415:SF0; TYROSYL-DNA PHOSPHODIESTERASE 1; 1.
DR   Pfam; PF06087; Tyr-DNA_phospho; 1.
DR   SUPFAM; SSF56024; Phospholipase D/nuclease; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cytoplasm; Disease variant; DNA damage;
KW   DNA repair; Exonuclease; Hydrolase; Neurodegeneration; Nuclease; Nucleus;
KW   Phosphoprotein; Reference proteome; Repeat.
FT   CHAIN           1..608
FT                   /note="Tyrosyl-DNA phosphodiesterase 1"
FT                   /id="PRO_0000212486"
FT   REGION          1..101
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          400..403
FT                   /note="Interaction with DNA"
FT                   /evidence="ECO:0000269|PubMed:12470949"
FT   COMPBIAS        13..27
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        64..88
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        263
FT                   /note="Nucleophile"
FT                   /evidence="ECO:0000269|PubMed:12470949,
FT                   ECO:0000269|PubMed:15111055"
FT   ACT_SITE        493
FT                   /note="Proton donor/acceptor"
FT                   /evidence="ECO:0000269|PubMed:12470949,
FT                   ECO:0000269|PubMed:15111055"
FT   BINDING         265
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000269|PubMed:12470949"
FT   BINDING         495
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000269|PubMed:12470949"
FT   SITE            518
FT                   /note="Interaction with DNA"
FT                   /evidence="ECO:0000269|PubMed:12470949"
FT   MOD_RES         61
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         147
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         148
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   VAR_SEQ         1..25
FT                   /note="MSQEGDYGRWTISSSDESEEEKPKP -> MVISERLRLTSMPRPSLTRTSLS
FT                   AR (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.1"
FT                   /id="VSP_055765"
FT   VAR_SEQ         26..264
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.1"
FT                   /id="VSP_055766"
FT   VARIANT         95
FT                   /note="E -> D (in dbSNP:rs35114462)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_025817"
FT   VARIANT         101
FT                   /note="P -> L (in dbSNP:rs35455108)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_025818"
FT   VARIANT         134
FT                   /note="A -> T (in dbSNP:rs28365054)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_025819"
FT   VARIANT         187
FT                   /note="D -> G (in dbSNP:rs35271143)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_025820"
FT   VARIANT         304
FT                   /note="R -> Q (in dbSNP:rs34452707)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_025821"
FT   VARIANT         493
FT                   /note="H -> R (in SCAN1; reduces enzyme activity and leads
FT                   to the accumulation of covalent complexes between TDP1 and
FT                   DNA; dbSNP:rs119467003)"
FT                   /evidence="ECO:0000269|PubMed:12244316,
FT                   ECO:0000269|PubMed:15647511, ECO:0000269|PubMed:15920477,
FT                   ECO:0000269|PubMed:16141202, ECO:0000269|PubMed:17948061"
FT                   /id="VAR_017144"
FT   VARIANT         566
FT                   /note="P -> L (in autosomal recessive or sporadic
FT                   spinocerebellar ataxia affected Japanese individuals;
FT                   dbSNP:rs767298655)"
FT                   /evidence="ECO:0000269|PubMed:12244316"
FT                   /id="VAR_017145"
FT   VARIANT         569
FT                   /note="T -> A (in dbSNP:rs35973343)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_025822"
FT   MUTAGEN         263
FT                   /note="H->A: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:11572945,
FT                   ECO:0000269|PubMed:15111055"
FT   MUTAGEN         265
FT                   /note="K->A: Abolishes hydrolysis of the covalent
FT                   intermediate between the active site nucleophile and DNA."
FT                   /evidence="ECO:0000269|PubMed:11572945,
FT                   ECO:0000269|PubMed:15111055"
FT   MUTAGEN         265
FT                   /note="K->S: Reduces the activity to nearly undetectable
FT                   levels."
FT                   /evidence="ECO:0000269|PubMed:11572945,
FT                   ECO:0000269|PubMed:15111055"
FT   MUTAGEN         283
FT                   /note="N->A: No effect."
FT                   /evidence="ECO:0000269|PubMed:15111055"
FT   MUTAGEN         294
FT                   /note="Q->A: Slightly reduced hydrolysis of the covalent
FT                   intermediate between the active site nucleophile and DNA."
FT                   /evidence="ECO:0000269|PubMed:15111055"
FT   MUTAGEN         493
FT                   /note="H->A: 3000-fold reduction in activity; abolishes
FT                   hydrolysis of the covalent intermediate between the active
FT                   site nucleophile and DNA."
FT                   /evidence="ECO:0000269|PubMed:11572945,
FT                   ECO:0000269|PubMed:15111055"
FT   MUTAGEN         493
FT                   /note="H->N: 15000-fold reduction in activity."
FT                   /evidence="ECO:0000269|PubMed:11572945,
FT                   ECO:0000269|PubMed:15111055"
FT   MUTAGEN         495
FT                   /note="K->A: Abolishes hydrolysis of the covalent
FT                   intermediate between the active site nucleophile and DNA."
FT                   /evidence="ECO:0000269|PubMed:11572945,
FT                   ECO:0000269|PubMed:15111055"
FT   MUTAGEN         495
FT                   /note="K->S: 125-fold reduction in activity."
FT                   /evidence="ECO:0000269|PubMed:11572945,
FT                   ECO:0000269|PubMed:15111055"
FT   MUTAGEN         516
FT                   /note="N->A: Reduced hydrolysis of the covalent
FT                   intermediate between the active site nucleophile and DNA."
FT                   /evidence="ECO:0000269|PubMed:15111055"
FT   MUTAGEN         538
FT                   /note="E->A: Abolishes hydrolysis of the covalent
FT                   intermediate between the active site nucleophile and DNA."
FT                   /evidence="ECO:0000269|PubMed:15111055"
FT   CONFLICT        389
FT                   /note="A -> P (in Ref. 2; BAA91997)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        511
FT                   /note="L -> R (in Ref. 6; AAF65624)"
FT                   /evidence="ECO:0000305"
FT   TURN            149..151
FT                   /evidence="ECO:0007829|PDB:1JY1"
FT   HELIX           154..156
FT                   /evidence="ECO:0007829|PDB:1JY1"
FT   STRAND          166..169
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   HELIX           176..178
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   TURN            179..181
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   HELIX           185..188
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   HELIX           191..193
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   STRAND          196..202
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   STRAND          204..206
FT                   /evidence="ECO:0007829|PDB:1RGU"
FT   HELIX           208..214
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   HELIX           217..219
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   STRAND          224..228
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   HELIX           232..242
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   STRAND          248..252
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   STRAND          266..273
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   STRAND          275..280
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   HELIX           286..289
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   STRAND          291..293
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   STRAND          295..298
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   HELIX           319..328
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   HELIX           333..343
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   STRAND          352..357
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   STRAND          359..363
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   HELIX           364..369
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   HELIX           371..382
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   HELIX           389..391
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   STRAND          394..397
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   TURN            408..415
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   HELIX           416..421
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   STRAND          424..426
FT                   /evidence="ECO:0007829|PDB:5NWA"
FT   STRAND          437..440
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   HELIX           444..448
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   STRAND          450..452
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   HELIX           454..459
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   HELIX           464..467
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   HELIX           471..476
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   STRAND          477..479
FT                   /evidence="ECO:0007829|PDB:6MZ0"
FT   HELIX           483..485
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   STRAND          490..492
FT                   /evidence="ECO:0007829|PDB:6W4R"
FT   STRAND          495..500
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   STRAND          504..514
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   HELIX           519..522
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   STRAND          524..526
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   TURN            527..530
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   STRAND          531..534
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   STRAND          536..543
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   HELIX           545..548
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   STRAND          553..555
FT                   /evidence="ECO:0007829|PDB:6N0D"
FT   STRAND          568..570
FT                   /evidence="ECO:0007829|PDB:6DJD"
SQ   SEQUENCE   608 AA;  68420 MW;  F30202BD8329E5CE CRC64;
     MSQEGDYGRW TISSSDESEE EKPKPDKPST SSLLCARQGA ANEPRYTCSE AQKAAHKRKI
     SPVKFSNTDS VLPPKRQKSG SQEDLGWCLS SSDDELQPEM PQKQAEKVVI KKEKDISAPN
     DGTAQRTENH GAPACHRLKE EEDEYETSGE GQDIWDMLDK GNPFQFYLTR VSGVKPKYNS
     GALHIKDILS PLFGTLVSSA QFNYCFDVDW LVKQYPPEFR KKPILLVHGD KREAKAHLHA
     QAKPYENISL CQAKLDIAFG THHTKMMLLL YEEGLRVVIH TSNLIHADWH QKTQGIWLSP
     LYPRIADGTH KSGESPTHFK ADLISYLMAY NAPSLKEWID VIHKHDLSET NVYLIGSTPG
     RFQGSQKDNW GHFRLKKLLK DHASSMPNAE SWPVVGQFSS VGSLGADESK WLCSEFKESM
     LTLGKESKTP GKSSVPLYLI YPSVENVRTS LEGYPAGGSL PYSIQTAEKQ NWLHSYFHKW
     SAETSGRSNA MPHIKTYMRP SPDFSKIAWF LVTSANLSKA AWGALEKNGT QLMIRSYELG
     VLFLPSAFGL DSFKVKQKFF AGSQEPMATF PVPYDLPPEL YGSKDRPWIW NIPYVKAPDT
     HGNMWVPS
//
